One possible reason for this phenotype may be that estrogen receptors (ERs) regulate KDM4B in ER+ breast cancer,9 which makes KDM4B correlated to a subtype of cancer that is more effectively treated with Tamoxifen and other anti‐estrogens. This evidence concerns the gene KDM4B and breast cancer.